Navigation Links
Palatin Technologies, Inc. To Report Fiscal Year 2013 Third Quarter Results; Teleconference and Webcast to be held on May 14, 2013
Date:5/8/2013

CRANBURY, N.J., May 8, 2013 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE MKT: PTN) will announce its third quarter, fiscal year 2013 financial results on Tuesday, May 14, 2013 before the open of the U.S. financial markets.

Palatin will also conduct a conference call and live audio webcast hosted by its executive management team on May 14, 2013. The conference call will include an update on development of bremelanotide for female sexual dysfunction, including plans for Phase 3 clinical trials and results of the end-of-Phase 2 meeting with the U.S. Food and Drug Administration.Schedule for the Financial Results Press Release, Conference Call / Webcast 

  • 3Q Fiscal Year 2013 Financial Results Press Release
  • 5/14/2013 at 7:30 a.m. ET

  • 3Q Fiscal Year 2013 Conference Call-Live
    Domestic Dial-In Number
    International Dial-In Number
    Passcode
  • 5/14/2013 at 11:00 a.m. ET

    1-888-427-9419

    1-719-457-2648

    8591699

  • 3Q Fiscal Year 2013 Conference Call-Replay
    Domestic Dial-In Number
    International Dial-In Number
    Passcode
  • 5/14/2013-5/21/2013

    1-888-203-1112

    1-719-457-0820

    8591699

  • Webcast Live and Replay Access
  • http://www.palatin.com The webcast and replay can be accessed by logging on to the "Investor/Media Center-Webcasts"

    section of Palatin's website at http://www.palatin.comAbout Palatin Technologies, Inc.
    Palatin Technologies, Inc. is a biopharmaceutical company developing targeted, receptor-specific peptide therapeutics for the treatment of diseases with significant unmet medical need and commercial potential. Palatin's strategy is to develop products and then form marketing collaborations with industry leaders in order to maximize their commercial potential. For additional information, please visit http://www.palatin.com or follow us on Twitter at http://twitter.com/PalatinTech.


    '/>"/>
    SOURCE Palatin Technologies, Inc.
    Copyright©2012 PR Newswire.
    All rights reserved

    Related biology technology :

    1. Palatin Technologies Announces Notification of Patent Allowance On Melanocortin Receptor-Specific Peptides for Sexual Dysfunction
    2. Palatin Technologies To Present At The 25th Annual ROTH Conference
    3. Palatin Technologies, Inc. To Present At The Cowen & Company 33rd Annual Health Care Conference
    4. Palatin Technologies, Inc. Reports Second Quarter Fiscal Year 2013 Results; Teleconference and Webcast to be held on February 14, 2013
    5. Palatin Technologies, Inc. To Report Fiscal Year 2013 Second Quarter Results; Teleconference and Webcast to be held on February 14, 2013
    6. Palatin Technologies, Inc. to Present at 15th Annual BIO CEO & Investor Conference
    7. Palatin Technologies, Inc. to Present at the 24th Annual Piper Jaffray Healthcare Conference
    8. Palatin Technologies, Inc. Reports First Quarter Fiscal Year 2013 Results; Teleconference and Webcast to be held on November 14, 2012
    9. Palatin Technologies, Inc. To Present At The Lazard Capital Markets 9th Annual Healthcare Conference
    10. Palatin Technologies, Inc. To Report Fiscal Year 2013 First Quarter Results; Teleconference and Webcast to be held on November 14, 2012
    11. Palatin Technologies Reports Positive Results for Phase 2B Bremelanotide Female Sexual Dysfunction Trial
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:2/4/2016)... ... 04, 2016 , ... Many of the engineers at FireflySci, Inc. have been ... them apart from other cuvette manufacturers is their supercharged customer service and their extensive ... of this steady flow of inside information, they have recently revamped their manufacturing techniques ...
    (Date:2/3/2016)... Denmark , Feb. 3, 2016 Ascendis ... biotechnology company that applies its innovative TransCon technology to ... present at an upcoming investor conference.Event:2016 Leerink Partners Global ... NY Date:  , Wednesday, February 10, 2016 Time:  ... www.ascendispharma.com . --> An audio webcast ...
    (Date:2/3/2016)... (PRWEB) , ... February 03, 2016 , ... ... validating a series of potential targets (epitopes) specific to misfolded, propagating strains of ... to create specific monoclonal antibody therapeutics for Alzheimer’s. , Following on from the ...
    (Date:2/3/2016)... PALO ALTO, Calif. , Feb. 3, 2016 /PRNewswire/ ... the sale of AlphaImpactRx , a leading provider ... consumer health companies to IMS Health , a ... industry. AlphaImpactRx,s complementary offerings, capabilities and technologies will be ... the company,s growing global primary market research capabilities. ...
    Breaking Biology Technology:
    (Date:2/3/2016)... 3, 2016 ... the "Emotion Detection and Recognition Market ... Others), Software Tools (Facial Expression, Voice Recognition ... Regions - Global forecast to 2020" ... http://www.researchandmarkets.com/research/d8zjcd/emotion_detection ) has announced the addition ...
    (Date:2/2/2016)... YORK , Feb. 2, 2016 ... of that Rising Market Are you interested ... analysis forecasts revenues for checkpoint inhibitors. Visiongain,s report ... market, submarket, product and national level. Avoid ... discover what progress, opportunities and revenues those emerging ...
    (Date:2/2/2016)... 2, 2016  Based on its recent analysis ... recognizes US-based Intelligent Retinal Imaging Systems (IRIS) with ... for New Product Innovation. IRIS, a prominent cloud-based ... America , is poised to set the ... retinopathy market. The IRIS technology presents superior price-performance ...
    Breaking Biology News(10 mins):